WebbName: Denosumab Shared Care Guideline Page 1 of 4 Version: 1.2 Issue Date: March 2013 Review Date: March 2015 Shared Care Guidelines DRUG: Denosumab (Prolia®) Indication: Osteoporosis Licensing Information: Prolia is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. WebbShared Care Guideline Shared Care Guideline for prescribing Denosumab (Prolia®) INDICATION Denosumab (Prolia ®) is recommended as an option for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Denosumab has been approved by NICE (TA 204). Denosumab is recommended as a treatment option for …
Denosumab (Prolia®) - GMMMG
WebbShared Care Guideline Denosumab Treatment of osteoporosis in post menopausal women Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing the prescribing of denosumab for indications listed below. Indication NICE guidance recommends denosumab as a treatment option WebbThe shared care proposal includes the use of denosumab (Prolia ) for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures where oral therapies are contraindicated or not tolerated. iphone dolphin wallpaper
Northern Ireland Electronic Care Record (NIECR) nidirect
Webb17 maj 2024 · Amgen Ireland Ltd . XGEVA . No Recent Update. PIL 28/07/22 SPC 26/07/22 No A. Denosumab . Amgen Ireland Ltd . Brought to you by. About. Help; About; Contact Us; Legal. ... Denosumab. Medicine Status PIL SPC XPIL Legal Category Active Ingredient(s) Company . Prolia . No Recent Update. PIL 17/05/22 SPC 17/05/22 No A. Denosumab . … WebbPlease note this Shared Care Framework refers to Denosumab 60mg injection (Prolia) which is approved as an AMBER Drug within Hull and East Riding. Denosumab 120mg … Webb8 juli 2024 · About the Shared Care Protocols. SCPs are clinically focussed and provide the information required to support safe and effective shared care for the specified medicines. They include licensed indications and established off-label uses. Standardised templates will improve patient safety, reduce duplication and reduce inequity of access. iphone dolphin emulator